A descriptive study of racial inequalities in mortality from hepatocellular cancer before and after licensure of lifesaving drugs for hepatitis C virus in the United States

BACKGROUND: Since 1979, mortality from hepatocellular cancer (HCC) has doubled in the United States (US). Lifesaving drugs, prohibitively expensive for some, were approved and marketed to treat hepatitis C virus (HCV), a major risk factor for HCC, beginning in 1997. After the prior introduction of o...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:EClinicalMedicine
Egile Nagusiak: Levine, Robert S, Mejia, Maria C, Salemi, Jason L, Gonzalez, Sandra J, Aliyu, Muktar H, Husaini, Baqar A, Zoorob, Roger J, Hennekens, Charles H
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2020
Gaiak:
Research paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7200781/
https://ncbi.nlm.nih.gov/pubmed/32382721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2020.100350
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak